Xenetic enters manufacturing agreement with Catalent for DNase clinical supply up to $5M

Xenetic Biosciences, Inc.

Estimated project cost up to ~$5M for cGMP manufacturing of Human DNase I over ~17 months.
Catalent to provide manufacturing services for clinical supply to support planned Phase 1 study.
DNase platform targets NETs to enhance efficacy of immunotherapies and chemotherapies in solid tumors.
Initial indication focus includes pancreatic carcinoma, a multi-billion-dollar market.
CEO Jeffrey Eisenberg says this is an important step towards first-in-human studies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.